The estimated Net Worth of Colin Sandercock is at least $643 Tausend dollars as of 5 August 2020. Mr. Sandercock owns over 13,274 units of Cue Biopharma Inc stock worth over $17,935 and over the last 7 years he sold CUE stock worth over $0. In addition, he makes $625,514 as Senior Vice President, General Counsel und Secretary at Cue Biopharma Inc.
Sign up
Mr. Sandercock CUE stock SEC Form 4 insiders trading
Colin has made over 3 trades of the Cue Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 13,274 units of CUE stock worth $99,555 on 5 August 2020.
The largest trade he's ever made was buying 16,938 units of Cue Biopharma Inc stock on 6 June 2019 worth over $132,625. On average, Colin trades about 3,070 units every 36 days since 2017. As of 5 August 2020 he still owns at least 30,399 units of Cue Biopharma Inc stock.
You can see the complete history of Mr. Sandercock stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Colin Sandercock biography
Colin G. Sandercock J.D. serves as Senior Vice President, General Counsel, Secretary of the Company. Prior to joining Cue Biopharma, he was a partner at Perkins Coie LLP since July 2010, practicing in the areas of patent litigation, procurement, management and enforcement of domestic and foreign patent portfolio, licensing disputes, trademark disputes, and opinions relating to infringement, validity and freedom to operate. Mr. Sandercock holds a B.S. from Moravian College, an M.S.E. from the University of Pennsylvania and a J.D. from Catholic University, Columbus School of Law.
What is the salary of Colin Sandercock?
As the Senior Vice President, General Counsel und Secretary of Cue Biopharma Inc, the total compensation of Colin Sandercock at Cue Biopharma Inc is $625,514. There are 3 executives at Cue Biopharma Inc getting paid more, with Anish Suri having the highest compensation of $4,559,810.
How old is Colin Sandercock?
Colin Sandercock is 64, he's been the Senior Vice President, General Counsel und Secretary of Cue Biopharma Inc since 2017. There are 3 older and 15 younger executives at Cue Biopharma Inc. The oldest executive at Cue Biopharma Inc is Frederick Driscoll, 70, who is the Independent Director.
What's Colin Sandercock's mailing address?
Colin's mailing address filed with the SEC is C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON, MA, 02135.
Insiders trading at Cue Biopharma Inc
Over the last 7 years, insiders at Cue Biopharma Inc have traded over $1,426,672 worth of Cue Biopharma Inc stock and bought 1,194,685 units worth $5,848,356 . The most active insiders traders include Daniel R Passeri, Aaron G.L. Fletcher und Barry J. Simon. On average, Cue Biopharma Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,162. The most recent stock trade was executed by Anish Suri on 25 August 2023, trading 4,000 units of CUE stock currently worth $11,040.
What does Cue Biopharma Inc do?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
What does Cue Biopharma Inc's logo look like?
Complete history of Mr. Sandercock stock trades at Cue Biopharma Inc
Cue Biopharma Inc executives and stock owners
Cue Biopharma Inc executives and other stock owners filed with the SEC include:
-
Anish Suri,
President, Chief Scientific Officer -
Daniel Passeri,
Chief Executive Officer, Director -
Daniel R. Passeri M.Sc., MSc., J.D.,
CEO & Director -
Colin Sandercock,
Senior Vice President, General Counsel, Secretary -
Dr. Anish Suri Ph.D.,
Pres & Chief Scientific Officer -
Kerri-Ann Millar,
Chief Financial Officer -
Aaron Fletcher,
Independent Director -
Barry Simon,
Independent Director -
Peter Kiener,
Independent Director -
Frederick Driscoll,
Independent Director -
Frank Morich,
Independent Chairman of the Board -
Cameron Gray,
Independent Director -
Tamar Howson,
Director -
Kenneth Pienta,
Chief Medical Officer -
Kerri-Ann Millar,
Chief Financial Officer -
Dr. Kenneth J. Pienta,
Acting Chief Medical Officer -
Dr. Ronald D. Seidel III, Ph.D.,
Co-Founder -
Dr. Matteo Levisetti M.D.,
Sr. VP of Clinical Devel. -
Dr. Ronald D. Seidel III,
Exec. VP and Head of R&D -
Colin G. Sandercock J.D., MSE,
Sr. VP, Gen. Counsel & Sec. -
George B. Zavoico Ph.D.,
VP of Investor Relations & Corp. Devel. -
Dr. Steven C. Almo,
Co-Founder and Chairman of Scientific & Clinical Advisory Board -
Dr. Rodolfo J. Chaparro,
Co-Founder & Sr. Advisor -
Bethany Mancilla,
SVP and Chief Business Officer -
Ronald D. Iii Seidel,
EVP, Head of R&D -
Christopher A Marlett,
Director -
Anthony Digiandomenico,
Director -
Rodolfo Chaparro,
EVP, Head of Immunology -
Steven L Mcknight,
Director -
Patricia Nasshorn,
Chief Business Officer -
Matteo Levisetti,
Chief Medical Officer -
Michael J Fox,
-
Pamela Garzone,
-
Patrick Verheyen,
-
Lucinda Warren,
CHIEF BUSINESS OFFICER